The wound-healing process intricately involves a symphony of cell types—macrophages, fibroblasts, endothelial cells, and keratinocytes—all of which demonstrate dysfunction under diabetic conditions aggravated by oxidative stress and reactive oxygen species (ROS) surges. These cellular derangements precipitate ferroptotic cascades, profoundly impairing tissue regeneration. Emerging evidence suggests that modulating ferroptosis may hold the key to tipping the scales toward effective healing in diabetes-compromised tissue microenvironments.

Macrophages are central architects of inflammation regulation and tissue restoration, orchestrating debris clearance and cytokine secretion vital for extracellular matrix (ECM) remodeling. In diabetic wounds, ferroptosis disrupts macrophage polarization—the dynamic shift between pro-inflammatory (M1) and reparative (M2) phenotypes. Iron homeostasis intricately influences this polarization; optimal iron promotes M2 states, fostering healing through secretion of ECM-enhancing cytokines like CCL17 and CCL22. However, iron overload skews macrophages toward M1 polarization by amplifying ROS production and activity of acetylated p53 transcription factors, fueling persistent inflammation. Remarkably, inhibitors such as Ferrostatin-1 attenuate ferroptosis in macrophages, reducing inflammation and facilitating angiogenesis, partly mediated by upregulating nuclear factor-E2-related factor 2 (Nrf2), a master regulator of antioxidant defenses.

Fibroblasts, the principal architects of ECM synthesis and scar tissue formation, are not spared from ferroptosis’s detrimental influence. Under oxygen and glucose deprivation, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy fosters ferroptosis in dermal fibroblasts, delaying ischemic wound healing. Diabetic hyperglycemia exacerbates fibroblast dysfunction by activating ferroptotic pathways, impairing cellular survival, proliferation, and migration. Interventions targeting ferroptosis, such as the application of Ferrostatin-1 or platelet-rich plasma (PRP), have demonstrated restoration of fibroblast functionality and activation of pro-survival signaling cascades like phosphatidylinositol 3-kinase (PI3K)/AKT. Moreover, the novel approach of delivering secretory autophagosomes from endothelial cells to fibroblasts modulates iron overload and oxidative stress—reversing ferroptosis and enhancing wound closure. Intriguingly, senescent fibroblasts in diabetic wounds exhibit ferroptosis resistance due to impaired ferritinophagy, but enhancing NCOA4 expression reverses this trait, suggesting a complex interplay between cellular aging and ferroptotic susceptibility.

Endothelial cells, pivotal for neovascularization and vascular integrity, confront significant ferroptotic stress in diabetic milieus marked by reduced capillary density and impaired angiogenesis. High-glucose exposure detrimentally affects proliferation, migration, and barrier function of endothelial cells, with ferroptosis emerging as a key mediator. Ferrostatin-1 rescues endothelial cells by downregulating ferroptosis-related proteins, mitigating lipid peroxidation and ROS accumulation. PRP also conveys protective effects by diminishing ferroptosis, thus fostering regeneration. At the molecular level, Nrf2 orchestrates a defensive response by regulating genes like glutathione peroxidase 4 (GPX4) and glucose-6-phosphate dehydrogenase (G6PD), essential for counteracting oxidative damage. Activation of transient receptor potential ankyrin 1 (TRPA1) channels triggers Ca²⁺ influx and subsequent Nrf2 nuclear translocation, mechanistically suppressing ferroptosis and enhancing angiogenic potential. Additionally, natural compounds such as resveratrol and synthetic metabolites like 4-octyl itaconate bolster Nrf2 signaling, alleviating ferroptosis in endothelial cells and promoting wound repair. Notably, immune cell interactions, specifically neutrophil extracellular traps (NETs), may exacerbate endothelial ferroptosis by inhibiting PI3K/AKT pathways, further compromising wound vascularization.

Keratinocytes, the frontline defenders forming the epidermal barrier, also succumb to ferroptotic insults in diabetic wounds. Advanced glycation end products (AGEs) accumulate in diabetes, provoking oxidative stress and lipid peroxidation that induce keratinocyte ferroptosis. The autophagy-lysosome pathway, crucial for degrading pro-ferroptotic enzymes such as acyl-CoA synthetase long-chain family member 4 (ACSL4), is impaired due to reduced expression of sequestosome 1 (SQSTM1), further sensitizing keratinocytes to ferroptotic death. Cutting-edge studies have revealed that exosomes derived from coenzyme Q10-treated mesenchymal stem cells (MSCs) transport microRNAs that suppress ACSL4 expression, protect keratinocytes, and accelerate re-epithelialization. Despite the complexity, targeting keratinocyte ferroptosis represents a fertile area for therapeutic development in diabetic wound management.

Beyond mammalian cells, bacterial pathogens in diabetic wounds present a significant challenge due to infection susceptibility and altered host defenses. Traditional antimicrobial approaches face limitations, prompting innovative strategies that exploit ferroptosis-like mechanisms to target bacteria. While many bacterial membranes lack polyunsaturated fatty acids (PUFAs) vulnerable to ferroptotic lipid peroxidation, some species can synthesize or integrate PUFAs, rendering them susceptible to ferroptosis-inducing agents. Recent advances include engineered nanomaterials and bio-heterojunctions designed to deliver iron ions directly to bacterial cells, triggering lipid peroxidation and ferroptosis-like death without harming host tissues. For instance, the creation of bio-heterojunctions combining Fe₂O₃, Ti₃C₂-MXene, and glucose oxidase effectively starves bacteria by depleting glucose, promoting targeted ferroptosis, while simultaneously protecting macrophages from oxidative damage. Similarly, microneedle hydrogels loaded with iron-based nanomaterials selectively induce intracellular reactive oxygen species in bacteria, demonstrating potent antimicrobial and wound-healing effects. Such approaches signify a paradigm shift in infected diabetic wound therapy.

The coordinated modulation of ferroptosis across diverse cellular players in the diabetic wound microenvironment highlights its role as a common denominator in pathological remodeling and repair failure. Therapeutic strategies harnessing ferroptosis inhibitors, activators, and nanotechnologies hold promise for simultaneously ameliorating chronic inflammation, restoring cellular vitality, and enhancing microbial clearance. Central to these advances is the transcription factor Nrf2, whose regulatory axis spans antioxidant response, iron metabolism, and ferroptosis suppression, making it a strategic target for pharmacological intervention.

Future research is poised to unravel the nuanced crosstalk between ferroptosis and other forms of regulated cell death in diabetic wounds, with implications extending to fibrosis, angiogenesis, and immune surveillance. Moreover, exploring the interplay between cellular senescence, autophagy dysregulation, and ferroptosis resistance could yield transformative insights into chronic wound recalcitrance. The integration of bioengineering and nanomedicine offers exciting venues for precision delivery of ferroptosis modulators, enhancing safety and efficacy.

In closing, the burgeoning field of ferroptosis research redefines our understanding of diabetic wound pathology and treatment. By decoding the iron-dependent, lipid peroxidation-driven mechanisms that disrupt multiple cell types—macrophages, fibroblasts, endothelial cells, keratinocytes—and employing innovative ferroptosis-targeting therapies against both host and bacterial cells, we edge closer to resolving a pervasive medical challenge. This pioneering science not only illuminates fundamental biological processes but also ushers in a new era of therapeutic possibilities for diabetic patients worldwide.

Subject of Research: The role and mechanisms of ferroptosis in the repair and healing of diabetic wounds.

Article Title: Research progress on the role and mechanisms of ferroptosis in diabetic wound repair.

Article References:
Zhang, W., He, H., Chen, S. et al. Research progress on the role and mechanisms of ferroptosis in diabetic wound repair. Cell Death Discov. 11, 515 (2025). https://doi.org/10.1038/s41420-025-02808-y

Image Credits: AI Generated

DOI: 10.1038/s41420-025-02808-y

Keywords: Ferroptosis, diabetic wounds, macrophages, fibroblasts, endothelial cells, keratinocytes, iron homeostasis, lipid peroxidation, Nrf2, oxidative stress, wound healing, antimicrobial therapy, nanomedicine

ZKSCAN5, a transcription factor belonging to the ZKS family, has emerged as a key player in cellular homeostasis and survival mechanisms. Located on chromosome 19 in humans, ZKSCAN5 has been implicated in various cellular processes, including proliferation and apoptosis. The recent study by Liu et al. highlights the intricate pathways through which ZKSCAN5 exerts its influence on ferroptosis, suggesting novel therapeutic avenues for targeting ferroptosis in diseases such as cancer.

The study begins with an exploration of the PI3K/AKT signaling pathway, a critical regulator of various cellular processes. This pathway acts as a signal transducer for growth factors and plays a vital role in cell survival and proliferation. Disruption of the PI3K/AKT pathway has been associated with several diseases, particularly cancer, where uncontrolled cell growth and resistance to apoptosis are often observed. The effects of ZKSCAN5 on the PI3K/AKT axis underscore its potential as a modulator in cellular responses to stress conditions.

Furthermore, the investigation highlights the interaction between ZKSCAN5 and SREBP2 (Sterol Regulatory Element-Binding Protein 2), a key regulator of lipid metabolism. SREBP2 is crucial for the synthesis of cholesterol and fatty acids, linking metabolic states to ferroptosis. By regulating SREBP2, ZKSCAN5 appears to influence lipid composition and vulnerability to ferroptotic cell death, offering insights into how metabolic reprogramming can alter cell fate.

Liu and colleagues also delve into the role of APOC1, a gene traditionally associated with lipoprotein metabolism. The study reveals that APOC1 modulates ferroptosis via the SLC1A5 (Solute Carrier Family 1 Member 5) transporter, which is responsible for the uptake of neutral amino acids, particularly glutamine. The intricate interplay between APOC1 and SLC1A5 adds another layer of complexity to the regulation of cell death, suggesting that alterations in nutrient transport can significantly influence ferroptotic signaling.

In experiments designed to elucidate the mechanisms involved, the researchers employed a combination of gene knockdown and overexpression techniques to assess the effects of ZKSCAN5 on ferroptosis. Their findings suggest that elevated levels of ZKSCAN5 correspond to enhanced resistance to ferroptosis under conditions of oxidative stress, indicating the potential for therapeutic targeting of this transcription factor in iron-related disorders.

The significance of these findings extends beyond basic science, implicating ZKSCAN5 as a potential biomarker for diseases where ferroptosis plays a crucial role, such as neurodegeneration and fibrosis. The researchers propose that manipulation of the ZKSCAN5 pathway may offer a therapeutic strategy to enhance ferroptotic cell death in cancer cells, thereby improving the efficacy of conventional chemotherapeutics, which often rely on inducing apoptosis in neoplastic cells.

Moreover, the study aligns with trends in cancer research, showcasing how metabolic interventions may provide new angles for treatment. The convergence of lipid metabolism and ferroptosis introduces a paradigm shift in our understanding of cancer biology, emphasizing the importance of metabolic pathways in dictating cellular outcomes during stress responses.

Interestingly, ZKSCAN5’s regulation of APOC1 and subsequent effects on ferroptosis have sparked discussions about its potential role in aging and age-related diseases. As our understanding of how cellular metabolism influences longevity evolves, ZKSCAN5 may be another piece in the puzzle, revealing how our bodies manage iron, lipids, and cell death across the lifespan.

In summary, Liu et al.’s research represents a critical advancement in our understanding of ferroptosis and its regulation. By unraveling the connections between ZKSCAN5, APOC1, and key signaling pathways, the study not only enriches our basic knowledge of cell death mechanisms but also paves the way for innovative therapeutic approaches targeting ferroptosis in a variety of diseases.

The relevance of these findings resonates with a broad audience, highlighting the dynamic interplay between genetics, metabolism, and cell death. As the scientific community continues to pursue breakthroughs in cancer therapy and regenerative medicine, the insights provided by this study could significantly impact future research trajectories.

As the implications of ZKSCAN5’s function unfold, it is crucial for researchers to continuously explore this nexus of pathways, consider potential off-target effects, and evaluate the broader implications of manipulating such critical regulators in therapeutic contexts. The journey of understanding and targeting ferroptosis is just beginning, and studies like this serve as vital stepping stones in this complex landscape of cell biology and medicine.

The exploration into ZKSCAN5 regulation also prompts deeper inquiries into how unique genetic variations across populations may impact susceptibility to ferroptosis-related disorders. As we prepare to merge genetic research with clinical applications, these insights might aid in personalizing therapies for patients, based on their unique genetic and metabolic profiles.

With the burgeoning field of ferroptosis research, Liu et al.’s findings will likely be a cornerstone for further investigations, adding layers of complexity to our understanding of how cellular environments dictate life and death decisions within cells. As we continue to explore the implications of their results, future studies may unlock even more secrets of this fascinating process, potentially leading to groundbreaking interventions against a range of health conditions.

In conclusion, the interplay between ZKSCAN5 and ferroptosis elucidated by Liu and colleagues not only enhances our comprehension of cell death but also inspires a new wave of therapeutic hypotheses that challenge existing paradigms in treatment strategies for cancer and beyond. As we delve deeper into the molecular intricacies of life and death decisions in cells, continued research in this area promises significant advancements in medical science and clinical practice.

Subject of Research: Regulation of ferroptosis by ZKSCAN5 and its impact on metabolism.

Article Title: ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis.

Article References:

Liu, Y., Qi, Z., Yang, S. et al. ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis. J Transl Med 23, 1020 (2025). https://doi.org/10.1186/s12967-025-07092-z

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07092-z

Keywords: Ferroptosis, ZKSCAN5, APOC1, PI3K/AKT, SREBP2, SLC1A5, cancer therapy, cell metabolism.